Welcome to our dedicated page for Iris Acquisition II news (Ticker: IRABU), a resource for investors and traders seeking the latest updates and insights on Iris Acquisition II stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Iris Acquisition II's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Iris Acquisition II's position in the market.
Iris Acquisition Corp II (NYSE: IRABU) priced a $150,000,000 initial public offering of 15,000,000 units at $10.00 per unit, each unit containing one Class A ordinary share and one-half redeemable warrant. Whole warrants exercisable at $11.50 arise after the SPAC combination or 12 months post-Effective Date.
Units are expected to begin trading on NYSE as IRABU on February 3, 2026, with separate trading of shares and warrants as IRAB and IRABW. The offering is expected to close February 4, 2026, with a 45-day 2,250,000-unit over-allotment option for the underwriter.
